JA
Therapeutic Areas
Supernus Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SPN-820/821 | Treatment-Resistant Depression | Phase 3 |
| SPN-817 | Severe Epilepsy | Phase 2 |
| ZURZUVAE (zuranolone) | Postpartum Depression | Approved |
| QELBREE (viloxazine ER) | ADHD | Approved |
Leadership Team at Supernus Pharmaceuticals
TC
Timothy C. Dec
Senior Vice President, Chief Financial Officer
KT
Kevin T. Anderson, Esq.
Compliance Officer